GOTHENBURG, Sweden—Mölnlycke Health Care, a MedTech company, announced a €115 million, approximately $134 million USD, expansion of its wound care manufacturing capacity in Brunswick, Maine.
The company said this move is a key part of its ongoing localisation strategy, aimed at producing products where they are sold. It addresses increasing United States customer demand.
"This expansion strengthens our U.S. presence and our mission to free patients and caregivers from the burden of wounds," said Zlatko Rihter, CEO of Mölnlycke. "With increased manufacturing capacity, we’re ready to meet the growing needs of our customers and take our U.S. growth to the next level."
Over the next five years, Mölnlycke will invest around €115 million to secure the supply of Mölnlycke's wound care products in the medtech market. The expansion will create new job opportunities, increasing the local workforce by 10%, as well as engaging local contractors.
The facility will utilize renewable energy sources like wind and solar power.
Additionally, the expansion will integrate machinery and technical equipment from U.S. suppliers to enable production of advanced wound care products.
“This expansion is a very big deal and the result of over a year’s hard work," said Chris Biddle, general manager of U.S. manufacturing for Wound Care. "Besides creating new jobs, it will drive workforce development and bring technological advancements. It’s a win for Mölnlycke, for the local community and for patients. We’re excited about the positive impact it will have locally in Maine and across the broader U.S. health care landscape.”